A fluorescence-based assay for N-myristoyltransferase activity by Goncalves, V et al.
A fluorescence-based assay for N-myristoyltransferase activity
Victor Goncalvesa, James A. Branniganb, Emmanuelle Thinona, Tayo O. Olaleyea,
Remigiusz Serwaa, Salvatore Lanzaronea, Anthony J. Wilkinsonb, Edward W. Tatea,*, and
Robin J. Leatherbarrowa,*
aDepartment of Chemistry, Imperial College London, London, SW7 2AZ, United Kingdom
bStructural Biology Laboratory, Department of Chemistry, University of York, York, YO10 5DD,
United Kingdom
Abstract
N-myristoylation is the irreversible attachment of a C14-fatty acid, myristic acid, to the N-terminal
glycine of a protein via formation of an amide bond. This modification is catalyzed by myristoyl-
CoA : protein N-myristoyltransferase (NMT), an enzyme ubiquitous in eukaryotes that is up-
regulated in several cancers.
Here we report a sensitive fluorescence-based assay to study the enzymatic activity of human
NMT1 and NMT2, based on detection of coenzyme A by 7-diethylamino-3-(4-maleimido-
phenyl)-4-methylcoumarin. We also describe expression and characterization of NMT1 and
NMT2, and assay validation with small molecule inhibitors. This assay should be broadly
applicable to NMTs from a range of organisms.
Keywords
N-myristoyltransferase (NMT); fluorescence; 7-diethylamino-3-(4-maleimido-phenyl)-4-
methylcoumarin (CPM); coenzyme A; screening
Myristoyl-coenzyme A : protein N-myristoyltransferase (N-myristoyltransferase, NMT) is a
ubiquitous enzyme in eukaryotes that catalyzes co- and post-translational transfer of a C14
saturated fatty acid (myristic acid) from myristoyl-coenzyme A (myristoyl-CoA) to the N-
terminal glycine residue of target proteins [1] (Fig. 1A). NMT was first identified in yeast
[2], and subsequently characterized in fungi, parasitic protozoa, insects, plants, humans and
other mammals. N-myristoylation of proteins can promote reversible protein-protein
interactions, enhance interactions of the protein with the membrane and change protein
stability [1]. The role of myristoylation is still not entirely understood, and not all
myristoylated proteins have been experimentally determined [3; 4]. However, in humans,
protein myristoylation is connected with several diseases including cancer [5], genetic
disorders [6] and infection [7]. In Homo sapiens, NMT is encoded by two distinct genes,
Nmt1 and Nmt2, and RNA interference experiments suggest that Nmt1 knockdown inhibits
tumor growth, making NMT1 a potential target for the development of novel anti-cancer
therapies [8]. The host myristoylation is essential for the formation of HIV viral capsids,
suggesting potential for mammalian NMT inhibitors as anti-viral agents [9]. Furthermore,
NMT is established as a promising anti-fungal [10] and anti-parasitic drug target, for
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example in African sleeping sickness [11; 12], malaria [13] and leishmaniasis [14; 15]. An
effective in vitro enzyme assay is required for drug discovery against NMT; the few assays
reported in detail to date are based on detection of a radioisotopic label in a myristoylated
peptide or protein [13; 16]. Such assays allow sensitive measurements, but are
discontinuous, expensive, and require handling and disposal of radioactive materials.
Herein we report the development of a robust fluorogenic assay for NMT activity suitable
for continuous reaction monitoring and end-point assays. This assay monitors coenzyme A
(CoA) production in real time using a pro-fluorescent probe, 7-diethylamino-3-(4-
maleimido-phenyl)-4-methylcoumarin (CPM), a commercially available coumarin
derivative containing a thiol-reactive maleimide [17] (Fig. 1B). The maleimide quenches
coumarin fluorescence, but the in situ reaction with CoA thiol generated during
myristoylation results in release of fluorescence.
The proteins used for this study are the catalytic domains of human NMT isoforms 1 and 2.
These proteins share 83% sequence identity over 388 amino acids and lack the long N-
terminal extensions involved in NMT subcellular targeting [18] (Supplementary data, Fig
S1). Details of gene constructs, protein production and purification may be found in
Supplementary Data. The assay was developed in 96-well black polypropylene microplates
(Greiner Bio-One, UK) and reagent solutions were prepared in a buffer containing 20 mM
potassium phosphate (pH 7.9-8.0) with 0.5 mM EDTA, 0.1% (v/v) Triton® X-100 and a
final concentration of 2.7% (v/v) DMSO. Thiol-containing reagents should be avoided as
they react with CPM and interfere with the assay. Fluorescence readings were obtained on a
SpectraMax M2e microplate reader (Molecular Devices, Canada) or an EnVision Xcite
reader (Perkin Elmer, UK). The peptide H-Gly-Ser-Asn-Lys-Ser-Lys-Pro-Lys-NH2 (Hs
pp60src(2-9)), derived from the N-terminal sequence of myristoylated Homo sapiens proto-
oncogene tyrosine kinase pp60src [19], was used as substrate for both human NMTs.
10 μL of a 10% DMSO/water (v/v) solution, 25 μL of myristoyl-CoA solution, 50 μL of
NMT (final concentration: 6.3 nM) and 10 μL of CPM solution (final concentration: 8 μM)
were combined in an assay well. The enzymatic reaction was started by adding 15 μL of
peptide substrate solution and fluorescence intensity was monitored over 30 minutes at 1
minute intervals (excitation 380 nm, emission at 470 nm) at 25 °C. The initial velocity was
calculated over the first 4 minutes of the experiment after subtraction of the background
fluorescence (measured in the absence of enzyme). The Michaelis-Menten (Km) constant of
Hs pp60src(2-9) was determined using a saturating concentration of the co-substrate,
myristoyl-CoA (30 μM). Under these conditions, the peptide Hs pp60src(2-9) displayed a Km
of 2.76 ± 0.21 μM and 2.77 ± 0.14 μM for NMT1 and NMT2 respectively. Subsequently,
the Km of myristoyl-Co A was determined in the presence of a saturating concentration (30
μM) of Hs pp60src(2-9) substrate. This experiment led to Km values of 8.24 ± 0.62 μM and
7.24 ± 0.79 μM for NMT1 and NMT2 respectively, which are in good agreement with
previously reported data (7.6 μM for NMT1 using pp60v-src(2-17) as substrate) [20].
While continuous assays are generally preferred for analytical purposes, they are time-
consuming and unsuitable for the screening of large compound libraries; we therefore
investigated the feasibility of an endpoint assay. A suitable enzyme concentration (6.3 nM)
was selected to give a linear reaction rate over 30 minutes at 25 °C. If necessary, this
concentration can be reduced down to 2.1 nM which in these conditions gives a reasonable
signal to background ratio of ~ 2. Then, we examined the possibility of quenching the
reaction by acidifying the reaction mixture since the rate of the reaction between the
coenzyme A and CPM is strongly pH-dependent [21] (Supplementary data, Fig S2).
Screening a range of conditions, we found that addition of 60 μL of 0.1 M sodium acetate
buffer pH 4.75 (‘quenching solution’) 30 minutes into the assay immediately decreased the
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pH of the reaction solution to pH 4.9-5.1. At this pH, quenching the fluorogenic reaction and
giving a signal that remains stable over 8 hours (Supplementary data, Fig. S3).
To validate the assay, two known NMT inhibitors were evaluated against NMT1 and NMT2
(Fig. 2): 1, a pseudo-peptidic NMT inhibitor [22] and 2, a small molecule that has been
recently described as an inhibitor with low-nM affinity for Trypanosoma brucei NMT and
Homo sapiens NMT [11]. Inhibition assays were carried out using the endpoint method,
with final concentrations of 4 μM Hs pp60src(2-9) and 4 μM myristoyl-CoA. Briefly, the
inhibitor in 10% DMSO/water (10 μL), myristoyl-CoA (25 μL) and NMT (50 μL) solutions
were combined in a 96-well plate as described above, and the enzymatic reaction was started
by adding 25 μL of a solution containing 17.6 μM Hs pp60src(2-9) and 35.2 μM CPM in
assay buffer. The reaction was stopped after 30 minutes at 25 °C by adding 60 μL quenching
solution. Positive controls excluded inhibitor, negative controls excluded both NMT and
inhibitor. Under these assay conditions, the average Z′ value was between 0.7 - 0.9. The
apparent Km of the peptide was determined to be 2.66 ± 0.20 μM for NMT1 and 3.25 ± 0.22
μM for NMT2.
As expected, 1 behaved as an inhibitor of both human NMTs with IC50 values of 0.35 μM
and 0.51 μM against NMT1 and NMT2 respectively, conforming to previously reported data
(IC50 = 0.50 ± 0.37 μM against NMT1) from a radioactive HPLC-based assay [22].
Similarly, 2 was tested against both human NMTs and led to IC50 values of 13.7 nM
(NMT1) and 14.4 nM (NMT2), similar to the result previously obtained against NMT1 with
a scintillation proximity assay (4 nM) [11].
In summary, this fluorogenic assay constitutes an attractive alternative to radioactive assays
in the search for NMT inhibitors. Moreover, the possibility of using it in either continuous or
endpoint mode makes it suitable both for kinetic/mechanistic studies and for high-
throughput screening. Whilst strongly nucleophilic reagents or inhibitors should be avoided
as they lead to increased background fluorescence, thiols in the enzyme are tolerated.
Although this assay was developed on human NMT1 and NMT2 it depends only on the
generation of CoA-SH, and could be readily adapted to the study of parasitic or fungal NMT
activity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
(A) NMT-catalysed N-myristoylation of target proteins. (B) Changes in fluorescence
emission spectra upon formation of the CPM-coenzyme A adduct in assay buffer at 25 °C
with excitation at 390 nm (RFU: relative fluorescence units).
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Fig. 2.
(A) Chemical structure of inhibitors 1 and 2. (B) Inhibition assay: IC50 values were
determined in the presence of 4 μM Hs pp60src(2-9) and 4 μM myristoyl-CoA. Data points
represent means of duplicates.
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